A carregar...
Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report
Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR-tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less tox...
Na minha lista:
Publicado no: | Exp Ther Med |
---|---|
Main Authors: | , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
D.A. Spandidos
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4487036/ https://ncbi.nlm.nih.gov/pubmed/26170967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2499 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|